Amgen's tezepelumab hits Phase 3 targets in esophageal disorder trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Amgen Inc (NASDAQ: AMGN) | Delayed: 435.35 -3.59 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $438.94 | 52 Week High | $176.85 | |||
| Open | $440.21 | 52 Week Low | $133.64 | |||
| Day High | $441.03 | P/E | 65.56 | |||
| Day Low | $435.00 | EPS | $6.64 | |||
| Volume | 593,826 | |||||
